Results 1 to 10 of about 14,336,962 (399)

Desmopressin in moderate hemophilia A patients: a treatment worth considering [PDF]

Haematologica, 2018
Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed.
Janneke I. Loomans, Marieke J.H.A. Kruip, Manuel Carcao, Shannon Jackson, Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Helen Platokouki, Erik Beckers, Jan Voorberg, Johanna G. van der Bom, Karin Fijnvandraat, for the RISE consortium   +12 more
doaj   +5 more sources

Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies

Medicina, 2023
Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a sudden and unexpected bleeding episode in a patient with no personal or family history of bleeding diathesis, and with a typical laboratory feature, i.e., a ...
Renato Marino
doaj   +1 more source

Investigating the nature of absorption lines in the Chandra X-ray spectra of the neutron star binary 4U 1820−30 [PDF]

, 2007
We use four Chandra gratings spectra of the neutron star low-mass X-ray binary 4U 1820–30 to better understand the nature of certain X-ray absorption lines in X-ray binaries, including the Ne II, Ne III, Ne IX, O VII, and O VIII lines.
D. Steeghs, E. M. Cackett, J. Homan, J. M. Miller, J. Raymond, Kaastra J. S., M. Méndez, M. van der Klis, R. Wijnands   +8 more
core   +11 more sources

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy

Frontiers in Immunology, 2020
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein.
Alex C. Chen, Xiaohe Cai, Chong Li, Liliane Khoryati, Marc A. Gavin, Carol H. Miao   +5 more
doaj   +1 more source

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Research and Practice in Thrombosis and Haemostasis, 2022
Background Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti ...
Claude Négrier, Johannes Oldenburg, Gili Kenet, Shannon L. Meeks, Jean‐Claude Bordet, Jens Müller, Sandra Le Quellec, Peter L. Turecek, Nikola Tripkovic, Yesim Dargaud   +9 more
doaj   +1 more source

Prolonged elevations in haemostatic and rheological responses following psychological stress in low socioeconomic status men and women [PDF]

, 2003
Low socioeconomic status (SES) and psychological stress are associated with increased risk of coronary heart disease, and both may influence haemostatic responses.
Kunz-Ebrecht, S., Lowe, G.D.O., Rumley, A., Steptoe, A.   +3 more
core   +1 more source

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia

Pilot and Feasibility Studies, 2018
Background The interest of health care agencies, private payers and policy makers for patient-reported outcomes (PRO) is continuously increasing. There is a substantial need to improve capacity to collect and interpret relevant PRO data to support ...
MW. Skinner, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, D. Noone, B. O’Mahony, D. Page, J. S. Stonebraker, A. Iorio   +9 more
doaj   +1 more source

Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]

, 2000
Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N., Geiersberger, U., Gesierich, Wolfgang, Hartenstein, R., Munker, Reinhold, Pohlmann, H.   +5 more
core   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

Haematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat, Jules Russick, Bagirath Gangadharan, Julie Rayes, Mathieu Ing, Jan Voorberg, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +7 more
doaj   +1 more source

Calcium Prevents Enhanced Degradation of Factor VIII in the Condition of Motion

Biology, 2023
Background: Hemophilia A and B induce recurrent bleeding episodes, mainly in skeletal muscles and joints that are in intermittent motion. We have previously demonstrated that intermittent motion contributes to increased degradation of factors VIII and IX.
Haim Cohen, Anat Keren-Politansky, Yonatan Crispel, Chen Yanovich, Keren Asayag, Yona Nadir   +5 more
doaj   +1 more source